EP0752990B1 — Benzisothiazoles derivatives as inhibitors of 5-lipoxygenase biosynthesis
Assigned to Pfizer Inc · Expires 1998-08-05 · 28y expired
What this patent protects
PCT No. PCT/IB95/00037 Sec. 371 Date Sep. 30, 1996 Sec. 102(e) Date Sep. 30, 1996 PCT Filed Jan. 18, 1995 PCT Pub. No. WO95/26346 PCT Pub. Date Oct. 5, 1995This invention relates to new heterocyclic compounds which are selective inhibitors of 5-lipoxygenase (5-LO). The new hetero…
USPTO Abstract
PCT No. PCT/IB95/00037 Sec. 371 Date Sep. 30, 1996 Sec. 102(e) Date Sep. 30, 1996 PCT Filed Jan. 18, 1995 PCT Pub. No. WO95/26346 PCT Pub. Date Oct. 5, 1995This invention relates to new heterocyclic compounds which are selective inhibitors of 5-lipoxygenase (5-LO). The new heterocyclic compounds are useful in inhibiting 5-LO per se and in the treatment or alleviation of inflammatory disease or condition, allergy or cardiovascular diseases in mammals wherein the inflammatory disease or condition includes but is not limited to asthma, arthritis, bronchi chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis, shock, atopic dermatitis, rheumatoid arthritis or osteoa This invention also relates to pharmaceutical compositions useful therefor.
Drugs covered by this patent
- Vascepa (ICOSAPENT ETHYL) · Amarin Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.